Tyrosine News and Research

RSS

Three-dimensional breast cell cultures reveal clues to breast cancer hidden inside stem cells

Stem cells and how to boost them is hot on the research agenda. But stopping them could be critical too, as evidence implicating stem cells in cancer is mounting.

3 May 2006

Therapy for metastatic renal cell carcinoma remains inadequate

The recent FDA approvals of the tyrosine kinase inhibitors sorafenib and sunitinib based on their activity in metastatic renal cell carcinoma have excited the medical oncology community

9 Mar 2006

New way to study proteins in live cells

For the first time, Johns Hopkins researchers were able to easily jumpstart the activity of a well-known cancer protein in live cells with a small molecule, a strategy that pinpointed key players in the cancer process and can be used to determine new therapeutic targets.

9 Mar 2006

SRY protein explains why men more likely to develop Parkinson's

Scientists at Prince Henry's Institute, Melbourne, and the University of California, Los Angeles, have discovered that SRY, the male protein that forms the testes is also produced in the brain region affected in Parkinson's disease.

24 Feb 2006

Monotherapy phase I clinical trials of novel cytotoxics, targeted therapeutics, antimetastatic agents/angiogenesis inhibitors, and immunotherapeutics/vaccines

Numerous novel oncology agents are currently in phase I monotherapy trials. New Medicine's Oncology KnowledgeBASE (nm|OK) has updated the records of 92 such agents with preclinical or clinical results reported during the 2005 meetings of the American Association for Cancer Research (AACR)

7 Feb 2006

Imatinib mesylate (Gleevec) may not be effective at treating kidney cancer

Mayo Clinic Cancer Center investigators report that imatinib mesylate (GleevecTM), the drug used to treat patients with gastrointestinal stromal cancers (GISTs), is not likely to be effective for patients with high grade renal cell carcinoma -- the most aggressive kidney cancer.

22 Dec 2005

AMN107 drug shows promise in leukemia resistance to Gleevec

The targeted agent AMN107 can produce dramatic benefits in patients with some forms of leukemia that are resistant to Gleevec, the standard therapy for these cancers, say researchers at The University of Texas M. D. Anderson Cancer Center.

13 Dec 2005

Ack1 molecule stimulates the aggressive growth of prostate cancer

The molecule, Ack1, a member of the growth-promoting tyrosine kinase gene family, stimulates tumor formation in part by signaling prostate cells to rid themselves of a tumor-suppressor protein. Normally, this suppressor protein would inhibit rapid cell growth by signaling the cell to destroy itself.

5 Dec 2005

Lowering calorie intake may help Parkinson's disease

A new Oregon Health & Science University and Portland Veterans Affairs Medical Center study suggests that early-stage Parkinson's disease patients who lower their calorie intake may boost levels of an essential brain chemical lost from the neurodegenerative disorder.

20 Nov 2005

Vanadium may help prepare the body to recover speedily from infections

Dietary supplements containing vanadium are used by body builders to help beef up muscles and by some diabetic people to control blood sugar. New research now suggests the naturally occurring but easily toxic element may help prepare the body to recover speedily from infections from gram-negative organisms such as E. coli.

11 Oct 2005

Gleevec's uses might expand even further

Gleevec (Imatinib) is a representative of the newest generation of cancer drugs. The substance conveys its potent anti-proliferative effect by selectively supressing the tyrosine kinase pathway. The Giessen lung researchers now issue a first report of this substance as a new target therapy for pulmonary hypertension

4 Oct 2005

Researchers at Johns Hopkins have identified three new genetic mutations in brain tumors

...a discovery that could pave the way for more effective cancer treatments.

27 Sep 2005

Mutations in receptor tyrosine kinases provide potential for highly-targeted cancer therapies

Scientists from J. Craig Venter Institute, Ludwig Institute for Cancer Research, and The Johns Hopkins University School of Medicine identified three novel mutations in two receptor tyrosine kinases in glioblastoma tumors using high throughput sequencing.

26 Sep 2005

John Hopkins scientists uncover "tags" that force proteins to cell surface

Johns Hopkins scientists have discovered internal "shipping labels" that allow -- and perhaps force -- hundreds if not thousands of proteins to get to the surface of cells and stay there.

22 Sep 2005

Tarceva should be tested as front-line therapy for older lung cancer patients

The tyrosine kinase inhibitor erlotinib (Tarceva) showed encouraging activity with relatively tolerable side effects in elderly, previously untreated patients with advanced non-small cell lung cancer (NSCLC), reports a team led by investigators from Dana-Farber Cancer Institute in Boston.

19 Sep 2005